Tumor necrosis factor-? inhibitors in therapy for psoriatic arthritis

Abstract

The paper presents the data available in the literature on the efficacy and tolerability of basic tumor necrosis factor α inhibitors (TNF α) etanercept,
adalimumab, infliximab in the treatment of psoriatic arthritis (PsA) and their effects on the major manifestations of this disease - cutaneous
and articular syndromes. It generalizes the authors experience in treating PA with infliximab. The value of TNF α inhibitors in the complex
therapy of PsA and indications for their use in this disease are analyzed